Anti-Mi-2 antibodies

Autoimmunity

Volumn 38, Issue 1, 2005, Pages 79-83

  Ghirardello, Anna ^a   Zampieri, Sandra ^a   Iaccarino, Luca ^a   Tarricone, Elena ^a   Bendo, Raffaele ^a   Gambari, Pier Franca ^a   Doria, Andrea ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLTRANSFERASE; AUTOANTIBODY; CELL NUCLEUS ANTIGEN; HLA DR7 ANTIGEN; MI 2 ANTIBODY; RECOMBINANT ANTIGEN; UNCLASSIFIED DRUG;

ARTICLE; DERMATOMYOSITIS; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOBLOTTING; MYOSITIS; NUCLEOSOME; PREDICTION; SENSITIVITY AND SPECIFICITY; SEROLOGY; TRANSCRIPTION REGULATION;

AUTOANTIBODIES; DERMATOMYOSITIS; DIAGNOSIS, DIFFERENTIAL; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HISTORY, 20TH CENTURY; HUMANS; IMMUNOGLOBULIN ISOTYPES; MYOSITIS; POLYMYOSITIS; SENSITIVITY AND SPECIFICITY;

EID: 17144367679     PISSN: 08916934     EISSN: None     Source Type: Journal    
DOI: 10.1080/08916930400022681     Document Type: Article

References (25)

1. Love LA, Leff RL, Fraser DD, Targoff IN, Dalakas M, Plotz PH, et al. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore) 1991;70:360-374.
2. Targoff IN, Miller FW, Medsger TA, Oddis CV. Classification criteria for the idiopathic inflammatory myopathies. Curr Opin Rheumatol 1997;9:527-535.
3. Hengstman GJ, Browuer R, Egberts WT, Seelig HP, Jongen PJ, Van Venrooij WJ, et al. Clinical and serological characteristics of 125 Dutch myositis patients. Myositis specific autoantibodies aid in the differential diagnosis of the idiopathic inflammatory myopathies. J Neurol 2002;249:69-75.
4. Zampieri S, Ghirardello A, Rossini K, Iaccarino L, Gambari PF, Doria A. Autoantibodies in idiopathic inflammatory myopathies. Basic Appl Myol 2002;12:27-31.
5. Reichlin M, Mattioli M. Description of a serological reaction characteristic of polymyositis. Clin Immunol Immunopathol 1976;5:12-20.
6. Nishikai M, Reichlin M. Purification and characterization of a nuclear non-histone basic protein (Mi-1) which reacts with anti-immunoglobulin sera and the sera of patients with dermatomyositis. Mol Immunol 1980;17:1129-1141.
7. Targoff IN, Reichlin M. The association between Mi-2 antibodies and dermatomyositis. Arthritis Rheum 1985;28:796-803.
8. Nilasena DS, Trieu EP, Targoff IN. Analysis of the Mi-2 autoantigen of dermatomyositis. Arthritis Rheum 1995;38:123-128.
9. Ge Q, Nilasena DS, O'Brien CA, Frank MB, Targoff IN. Molecular analysis of a major antigenic region of the 240-kD protein of Mi-2 autoantigen. J Clin Invest 1995;96:1730-1737.
10. Seelig HP, Moosbrugger I, Ehrfeld H, Fink T, Renz M, Genth E. The major dermatomyositis-specific Mi-2 autoantigen is a presumed helicase involved in transcriptional activation. Arthritis Rheum 1995;38:1389-1399.
11. Seelig HP, Renz M, Targoff IN, Ge Q, Frank MB. Two forms of the major antigenic protein of the dermatomyositis-specific Mi-2 autoantigen. Arthritis Rheum 1996;39:1769-1771.
12. Zang Y, LeRoy G, Seelig HP, Lane WS, Reinberg D. The dermatomyositis-specific autoantigen Mi2 is a component of a complex containing histone deacetylase and nucleosome remodeling activities. Cell 1998;95:279-289.
13. Wang HB, Zhang Y. Mi2, an auto-antigen for dermatomyositis, is an ATP-dependent nucleosome remodeling factor. Nucleic Acid Res 2001;15:2517-2521.
14. Mierau R, Dick T, Bartz-Bazzanella P, Keller E, Albert ED, Genth E. Strong association of dermatomyositis specific Mi-2 autoantibodies with a tryptophan at position 9 of the HLA-DRβ chain. Arthritis Rheum 1996;39:868-876.
15. Hengstman GJD, Van Venrooij WJ, Vencovsky J, Moutsopoulos HM, Van Engelen BGM. The relative prevalence of dermatomyositis and polymyositis in Europe exhibits a latitudinal gradient. Ann Rheum Dis 2000;59:141-142.
16. Okada S, Weatherhead E, Targoff IN, Wesley R, Miller FW. Global surface ultraviolet radiation intensity may modulate the clinical and immunologic expression of autoimmune muscle disease. Arthritis Rheum 2003;48:2285-2293.
17. Brouwer R, Hengstmam GJ, Vree Egberts W, Ehrfeld H, Bozic B, Ghirardello A, et al. Autoantibodies profiles in the sera of European patients with myositis. Ann Rheum Dis 2001;60:116-123.
18. Roux S, Seelig HP, Meyer O. Significance of Mi-2 autoantibodies in polymyositis and dermatomyositis. J Rheumatol 1998;25:395-396.
19. Rider LG, Miller FW, Targoff IN, Sherry DD, Samayoa E, Lindahl M, et al. A broadened spectrum of juvenile myositis. Myositis-specific autoantibodies in children. Arthritis Rheum 1994;10:1534-1538.
20. Feldman BM, Reichlin M, Laxer RM, Targoff IN, Stein LD, Silverman ED. Clinical significance of specific autoantibodies in juvenile dermatomyositis. J Rheumatol 1996;23:1794-1797.
21. Hausmanowa-Petrusewicz I, Kowalska-Oledzka E, Miller FW, Jarzabek-Chorzelska M, Targoff IN, Blaszczyk-Kostanecka M, et al. Clinical, serologic, and immunogenetic features in Polish patients with idiopathic inflammatory myopathies. Arthritis Rheum 1997;40:1257-1266.
22. Bohan A, Peter JB. Polymyositis and dermatomyositis. N Eng J Med 1975;292:344-347.
23. Dalakas MC. Polymyositis, dermatomyositis and inclusion-body myositis. N Eng J Med 1991;325:1487-1498.
24. Targoff IN. Laboratory testing in the diagnosis and management of idiopathic inflammatory myopathies. Rheum Dis Clin North Am 2002;28:859-890.
25. Hill CL, Zhang Y, Sigurgeirsson B, Pukkuda E, Mellemkjaer L, Airio A, et al. Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet 2001;357:96-100.